|
|
Makerere University Research Repository >
College of Health Sciences >
School of Health Sciences >
Research Articles (Health-Sciences) >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/123456789/1918
|
| Title: | Risk factors and seroprevalence of Hepatitis C among patients hospitalised at Mulago Hospital, Uganda |
| Authors: | O'Reilly, J.I
Ocama, P.
Opio, C. K.
Alfred, A.
Paintsil, E.
Seremba, E.
Sofair, A. N. |
| Keywords: | HIV/AIDS
Hepatitis C virus (HCV)
Uganda
Seroprevalence
Mulago Hospital |
| Issue Date: | 2011 |
| Publisher: | Hindawi Publishing Corporation |
| Citation: | O'Reilly, J.I., Ocama, p., Opio, C.K., Alfred, A., Painstil, E., Seremba, E., Sofair, A.N, (2011). Risk factors and seroprevalence of Hepatitis C among patients hospitalised at Mulago Hospital, Uganda. Journal of Tropical Medicine |
| Abstract: | The emergence of hepatitis C virus (HCV) and its associated sequelae in Africa is a cause for significant concern. Human
immunodeficiency virus (HIV) positive patients are at an increased risk of contracting HCV infection due to similar risk factors
and modes of transmission. We investigated the seroprevalence of hepatitis C in hospitalized HIV-positive and HIV-negative
patients in Mulago Hospital, an academic hospital in Uganda. Blood samples were first tested for HCV antibodies, and positive
tests were confirmed with HCV RNA PCR. We enrolled five hundred patients, half HIV-positive and half HIV negative. Overall,
13/500 patients (2.6%) tested positive for HCV antibodies. There was no difference in HCV antibody detection among HIVpositive
and HIV-negative patients. Out of all risk factors examined, only an age greater than 50 years was associated with HCV
infection. Traditional risk factors for concurrent HIV and HCV transmission, such as intravenous drug use, were exceedingly rare
in Uganda. Only 3 of 13 patients with detectable HCV antibodies were confirmed by HCV RNA detection. This result concurs
with recent studies noting poor performance of HCV antibody testing when using African sera. These tests should be validated in
the local population before implementation. |
| Gov't Doc # : | doi:10.1155/2011/598341 |
| URI: | http://hdl.handle.net/123456789/1918 |
| ISSN: | 1687-9686 |
| Appears in Collections: | Research Articles (Health-Sciences)
|
Files in This Item:
| File |
Description |
Size | Format |
|---|
| O'Reilly-chs-res.pdf | | 484Kb | Adobe PDF | View/Open |
|
All items in DSpace are protected by copyright, with all rights reserved.
|
